Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q92186

UPID:
SIA8B_HUMAN

ALTERNATIVE NAMES:
Sialyltransferase 8B; Sialyltransferase St8Sia II; Sialyltransferase X

ALTERNATIVE UPACC:
Q92186; Q4VAZ0; Q92470; Q92746

BACKGROUND:
The enzyme Alpha-2,8-sialyltransferase 8B, known alternatively as Sialyltransferase St8Sia II or Sialyltransferase X, is integral to the process of sialylation, where it adds sialic acid to glycoproteins. This modification is essential for the proper function of glycoproteins, affecting various biological processes including cell adhesion and signal transduction.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Alpha-2,8-sialyltransferase 8B offers a promising avenue for drug discovery. Given its critical role in glycoprotein modification, targeting this enzyme could lead to innovative treatments for conditions where glycoprotein function is compromised.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.